EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, RLAY: Relay Therapeutics Inc

24 Oct 25 15:59
LAST:

6.865

CHANGE:
 0.10		OPEN:
6.850		HIGH:
7.500		ASK:
0.000		VOLUME:
2.87M
CHG(%):
1.48		PREV:
6.760		LOW:
6.770		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 256.8507.5006.7706.8603.28M
23 Oct 256.4706.8306.3006.7601.51M
22 Oct 256.9807.0006.4456.4801.99M
21 Oct 257.1007.1606.8057.0401.93M
20 Oct 256.5957.1906.5957.1402.3M
17 Oct 256.3206.6276.3106.4901.96M
16 Oct 256.7006.7906.3406.5102.04M
15 Oct 256.0406.6206.0406.6101.37M
14 Oct 256.1206.2705.8506.0301.57M
13 Oct 256.6006.6806.1606.2701.35M

COMPANY PROFILE

Name:Relay Therapeutics Inc
About:Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:399 Binney Street, Cambridge, MA, United States, 02142
Website:https://www.relaytx.com
CUSIP:75943R102
CIK:0001812364
ISIN:US75943R1023
FIGI:BBG00DSS08K9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:6.860.1%
MA10:6.623.7%
MA20:6.1711.2%
MA50:4.8641.3%
MA100:4.1764.8%
MA200:3.7881.7%
STO9:56.46
STO14:61.68
RSI14:64.67 
WPR14:-21.37
MTM14:1.03
ROC14:0.18 
ATR:0.53 
Week High:7.509.2%
Week Low:6.309.0%
Month High:7.509.2%
Month Low:4.3281.7%
Year High:7.509.2%
Year Low:1.77287.9%